Cat. #161895
TOV-81D
Cat. #: 161895
Availability: 8-10 weeks
Organism: Human
Tissue: Ovary
Disease: Cancer
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Anne-Marie Mes-Masson and Diane Provencher
Institute: Centre Hospitalier de L’université de Montréal
Primary Citation: Provencher et al. 2000. In Vitro Cell Dev Biol Anim. 36(6):357-61. PMID 10949993
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: TOV-81D
- Cancer: Gynaecologic cancer
- Research fields: Cancer
- Organism: Human
- Tissue: Ovary
- Donor: Donor was 66 at diagnosis and had a familial history of breast and ovarian cancer. Patient was Grade 1-2 and Stage IIIC papillary serous adenocarcinoma and had undergone some pre-treatment prior to specimen collection in 1992. Germline BRCA2 mutation and nucleotide 8765delAG mutation in exon 20 was detected in this patient.
- Disease: Cancer
- Morphology: Flat morphology and are large surface cells with abundant cytoplasm. Epithelial morphology is similar to that of cell cultures derived from normal ovarian epithelium, does not form spheroids.
- Growth properties: Mixed
- Crispr: No
- Description: Epithelial ovarian cancer cell line derived from ovarian malignant tumor from patient with ovarian papillary serous cystadenocarcinoma
- Biosafety level: 1
- Additional notes: Doubling time is 4 days, cell line is not tumorigenic in mice, does not form colonies in soft agar, weak positive to Keratine 8,18 and Keratine 7 tests not done
Applications
- Application notes: Cell line grow as monolayer cultures on a solid surface.
Handling
- Format: Frozen
- Growth medium: OSE medium, 15% FBS, 2.5ug/ml fungizone and 50ug/ml gentamycin
- Shipping conditions: Dry Ice
- Storage conditions: Liquid Nitrogen
- Cultured in antibiotics: 2.5ug/ml fungizone and 50ug/ml gentamycin
- Str profiling: TH01: 7,9.3 / D21S11: 28,29 / D5S818: 12,13 / D13S317: 12 / D7S820: 10,12 / D16S539: 9,11 / CSF1PO: 11,12 / vWA: 17,19 / TPOX: 8 / AMEL: X
References
- Collins, et al. 2023. Front Endocrinol (Lausanne). 9,14:1162786. PMID: 37621654
- Raspaglio, et al. 2023. Cancers (Basel). 18,15(8):2361. PMID: 37190289
- Provencher et al. 2000. In Vitro Cell Dev Biol Anim. 36(6):357-61. PMID 10949993
